Patient description: A 42-year-old healthy woman came to the clinic to have her flu shot in early October. She works in a rehab center and has no underlying disease. It's her first time getting the vaccine this year. She is married for 5 years and uses barrier methods of contraception. Her menstrual cycle is irregular. She does not smoke. She is not on any medications. She exercises regularly for 30 minutes a day at least 5 days a week. She has no history of allergies to any food or drugs. Her past surgical history is significant for tonsillectomy and she is otherwise healthy.

Clinical trial eligibility criteria: eligible ages (years): 25.0-40.0,  Human Papillomavirus (HPV) Vaccine Subjects who the investigator believes that they can and will comply with the requirements of the protocol (e.g., completion of the diary cards, return for vaccination visits and for the follow-up visit) should be enrolled in the study. • The female subject should be married of Vietnamese origin, residing in Vietnam, and between, and including, 25 to 40 years of age at the time of the first vaccination Written informed consent obtained from the subject (prior to enrolment) Healthy subjects as established by medical history and clinical examination before entering into the study Subjects must have a negative urine pregnancy test Subjects of childbearing potential (i.e. active menstrual cycle) at the time of study entry must not be pregnant and must be abstinent (and if so, this must be documented in the source documents at each vaccination visit)  Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine within 30 days preceding the first dose of study vaccine, or planned use during the study period and up to one month after the last vaccine dose Subjects who have delivered recently or breastfeeding women must have completed a period of at least 3 months post-pregnancy and should not be breast-feeding in order to be enrolled in the study. Planning to become pregnant or likely to become pregnant (as determined by the investigator) or planning to discontinue contraceptive precautions during the study period Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs on 14 consecutive days within six months prior to the first vaccine dose and up to one month after the last dose of the vaccine. (For corticosteroids, this will mean prednisone, or equivalent, ≥ 0.5 mg/kg/day. Inhaled and topical steroids are allowed) Planned administration/administration of a vaccine not foreseen by the study protocol within 30 days before (Days and 30 days (i.e. Days 0 after the first dose of vaccine. However, the administration of tetanus toxoid vaccine up to 8 days before the first dose of study vaccine is allowed. Enrolment will be deferred until the subject is outside of specified window Previous vaccination against HPV or planned administration of any HPV vaccine other than that foreseen by the study protocol during the study period Any medically diagnosed or suspected immunodeficient condition such as human immunodeficiency virus (HIV) infection based on medical history and physical examination (no laboratory testing required) History of allergic disease, suspected allergy or reactions likely to be exacerbated by any component of the study vaccines, e.g. AS04, aluminium, MPL Hypersensitivity to latex (found in syringe-tip cap and plunger)